Skip to main content
Top
Published in: Rheumatology International 7/2008

01-05-2008 | Original Article

Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid

Authors: Jennifer Parker, Francisco Atez, Ronald G. Rossetti, Ann Skulas, Rakesh Patel, Robert B. Zurier

Published in: Rheumatology International | Issue 7/2008

Login to get access

Abstract

Interleukin-6 (IL-6) is a multifunctional cytokine which contributes to inflammation and tissue injury in several diseases. Thus, inhibition of IL-6 production may be a useful strategy for treatment of patients with diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). A synthetic nonpsychoactive cannabinoid, ajulemic acid (AjA), prevents joint damage in experimental arthritis. Results of experiments presented here indicate that addition of AjA (3–30 μM) to human monocyte derived macrophages in vitro reduces steady state levels of IL-6 mRNA and the subsequent secretion of IL-6 from LPS stimulated cells. Although AjA binds to and activates PPARγ, its anti IL-6 effects are PPARγ independent. These studies provide evidence to support the view that AjA may prove to be an effective, safe antiinflammatory agent.
Literature
1.
go back to reference Poupart P, Vandenabeele P, Cayphas S, VanSnick J, Haegman G, Kruys V, Fiers W, Content J (1987) B cell growth modulating and differentiating activity of recombinant human 26kd protein (BSF-2, HuIFN-beta 2, HPGF). EMBO J 6:1219–1224PubMed Poupart P, Vandenabeele P, Cayphas S, VanSnick J, Haegman G, Kruys V, Fiers W, Content J (1987) B cell growth modulating and differentiating activity of recombinant human 26kd protein (BSF-2, HuIFN-beta 2, HPGF). EMBO J 6:1219–1224PubMed
2.
go back to reference Abeles AM, Pillinger MH (2006) The role of synovial fibroblasts in rheumatoid arthritis-cartilage destruction and the regulation of matrix metalloproteinases. Bull Hosp Jt Dis 64:20–24 Abeles AM, Pillinger MH (2006) The role of synovial fibroblasts in rheumatoid arthritis-cartilage destruction and the regulation of matrix metalloproteinases. Bull Hosp Jt Dis 64:20–24
3.
go back to reference Legendre F, Bogdanowicz P, Boumediene K, Pujol JP (2005) Role of interleukin-6 (IL-6)/IL-6R induced signal transducers and activators of transcription and mitogen-activated protein kinase/extracelllular. J Rheumatol 32:1307–1316PubMed Legendre F, Bogdanowicz P, Boumediene K, Pujol JP (2005) Role of interleukin-6 (IL-6)/IL-6R induced signal transducers and activators of transcription and mitogen-activated protein kinase/extracelllular. J Rheumatol 32:1307–1316PubMed
4.
go back to reference Li SP, Goldman ND (1996) Regulation of human C-reactive protein gene expression by two synergistic IL-6 responsive elements. Biochemistry 35:9060–9068PubMedCrossRef Li SP, Goldman ND (1996) Regulation of human C-reactive protein gene expression by two synergistic IL-6 responsive elements. Biochemistry 35:9060–9068PubMedCrossRef
5.
go back to reference Dasgupta B, Corkill M, Kirkham B, Gibson T, Panayi G (2002) Serial estimation of interleukin-6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol 19:22–25 Dasgupta B, Corkill M, Kirkham B, Gibson T, Panayi G (2002) Serial estimation of interleukin-6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol 19:22–25
6.
go back to reference Choy EHS, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS (2002) Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. A randomized double blind, placebo-controlled dose escalation trial. Arthritis Rheum 46:3143–3150PubMedCrossRef Choy EHS, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS (2002) Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. A randomized double blind, placebo-controlled dose escalation trial. Arthritis Rheum 46:3143–3150PubMedCrossRef
7.
go back to reference Kaplin AI, Deshpande DM, Scott E, Krishnan C, Carmen JS, Shats I, Martinez T, Drummond J, Dike S, Pletnikov M, Keswani SC, Moran TH, Pardo CA, Calabresi PA, Kerr DA (2005) IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest 115:2731–2741PubMedCrossRef Kaplin AI, Deshpande DM, Scott E, Krishnan C, Carmen JS, Shats I, Martinez T, Drummond J, Dike S, Pletnikov M, Keswani SC, Moran TH, Pardo CA, Calabresi PA, Kerr DA (2005) IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest 115:2731–2741PubMedCrossRef
8.
go back to reference Dean GS, Tyrrell-Price J, Crawley E, Isenberg DA (2000) Cytokines and systemic lupus erythematosus. Ann Rheum Dis 59:243–251PubMedCrossRef Dean GS, Tyrrell-Price J, Crawley E, Isenberg DA (2000) Cytokines and systemic lupus erythematosus. Ann Rheum Dis 59:243–251PubMedCrossRef
9.
go back to reference Abel EL (1980) Marijuana: the first twelve thousand years. Plenum, New York Abel EL (1980) Marijuana: the first twelve thousand years. Plenum, New York
10.
go back to reference Burstein SH (1999) The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential. Pharmacol Therap 82:87–96CrossRef Burstein SH (1999) The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential. Pharmacol Therap 82:87–96CrossRef
11.
go back to reference Dajani EZ, Larsen KR, Taylor J, Dajani NE, Shawan TG, Neelema SD, Taylor MS, Dayton MT, Mir GN (1999) 1’,1’-dimethylheptyl-Δ8-tetrahydrocannabinol-11-oic acid: a novel orally effective cannabinoid with analgesic and anti-inflammatory properties. J Pharmacol Exp Ther 291:31–38PubMed Dajani EZ, Larsen KR, Taylor J, Dajani NE, Shawan TG, Neelema SD, Taylor MS, Dayton MT, Mir GN (1999) 1’,1’-dimethylheptyl-Δ8-tetrahydrocannabinol-11-oic acid: a novel orally effective cannabinoid with analgesic and anti-inflammatory properties. J Pharmacol Exp Ther 291:31–38PubMed
12.
go back to reference Zurier RB (2003) Prospects for cannabinoids as anti-inflammatory agents. J Cell Biochem 88:462–466PubMedCrossRef Zurier RB (2003) Prospects for cannabinoids as anti-inflammatory agents. J Cell Biochem 88:462–466PubMedCrossRef
13.
go back to reference Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U (2003) Analgesic effects of the synthetic CT3 on chronic neuropathic pain. JAMA 290:1757–1762PubMedCrossRef Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U (2003) Analgesic effects of the synthetic CT3 on chronic neuropathic pain. JAMA 290:1757–1762PubMedCrossRef
14.
go back to reference Zurier RB, Rossetti RG, Lane JH, Goldberg JM, Hunter SH, Burstein SH (1998) Dimethylheptyl-THC-11-oic acid: a nonpsychoactive anti-inflammatory agent with a cannabinoid template structure. Arthritis Rheum 41:163–170PubMedCrossRef Zurier RB, Rossetti RG, Lane JH, Goldberg JM, Hunter SH, Burstein SH (1998) Dimethylheptyl-THC-11-oic acid: a nonpsychoactive anti-inflammatory agent with a cannabinoid template structure. Arthritis Rheum 41:163–170PubMedCrossRef
15.
go back to reference Liu J, Li H, Burstein SH, Zurier RB, Chen JD (2003) Activation and binding of peroxisome proliferator-activated receptor gamma by a synthetic cannabinoid. Mol Pharmacol 65:983–992CrossRef Liu J, Li H, Burstein SH, Zurier RB, Chen JD (2003) Activation and binding of peroxisome proliferator-activated receptor gamma by a synthetic cannabinoid. Mol Pharmacol 65:983–992CrossRef
16.
go back to reference Burstein SH, Audette CA, Breuer A, Devane WA, Colodner S, Doyle SA, Mechoulam R (1992) Synthetic nonpsychotropic cannabinoids with potent anti-inflammatory, analgesic, and leukocyte anti-adhesion activities. J Med Chem 35:3135–3141PubMedCrossRef Burstein SH, Audette CA, Breuer A, Devane WA, Colodner S, Doyle SA, Mechoulam R (1992) Synthetic nonpsychotropic cannabinoids with potent anti-inflammatory, analgesic, and leukocyte anti-adhesion activities. J Med Chem 35:3135–3141PubMedCrossRef
17.
go back to reference Zurier RB, Rossetti RG, Burstein SH, Bidinger B (2003) Supression of human monocyte interleukin-1β production by ajulemic acid, a nonpsychoactive cannabinoid. Biochem Pharmacol 65:649–655PubMedCrossRef Zurier RB, Rossetti RG, Burstein SH, Bidinger B (2003) Supression of human monocyte interleukin-1β production by ajulemic acid, a nonpsychoactive cannabinoid. Biochem Pharmacol 65:649–655PubMedCrossRef
18.
go back to reference Kato T, Imatani T, Miura T, Minaguchi K, Saitoh E, Okudah K (2000) Cytokine-inducing activity of family 2 cystatins. Biol Chem 381:1143–1147PubMedCrossRef Kato T, Imatani T, Miura T, Minaguchi K, Saitoh E, Okudah K (2000) Cytokine-inducing activity of family 2 cystatins. Biol Chem 381:1143–1147PubMedCrossRef
19.
go back to reference Zingarelli B, Cook JA (2005) Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock 23:393–399PubMedCrossRef Zingarelli B, Cook JA (2005) Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock 23:393–399PubMedCrossRef
20.
go back to reference Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916PubMedCrossRef Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916PubMedCrossRef
21.
go back to reference Matsumoto T, Tsurumoto T, Shindo H (2006) Interleukin-6 levels in synovial fluids of patients with rheumatoid arthritis correlated with the infiltration of inflammatory cells in synovial membrane. Rheumatol Int 26:1096–1100PubMedCrossRef Matsumoto T, Tsurumoto T, Shindo H (2006) Interleukin-6 levels in synovial fluids of patients with rheumatoid arthritis correlated with the infiltration of inflammatory cells in synovial membrane. Rheumatol Int 26:1096–1100PubMedCrossRef
22.
go back to reference Reddy SV (2004) Regulatory mechanisms operative in osteoclasts. Crit Rev Eukaryot Gene Expr 14:255–270PubMedCrossRef Reddy SV (2004) Regulatory mechanisms operative in osteoclasts. Crit Rev Eukaryot Gene Expr 14:255–270PubMedCrossRef
23.
go back to reference Alonzi TE, Fattori E, Lazzarro D, Costa P, Probert GK, DeBendetti F, Poli V, Ciliberto G (1998) Interleukin-6 is required for the development of collagen induced arthritis. J Exp Med 187:461–468PubMedCrossRef Alonzi TE, Fattori E, Lazzarro D, Costa P, Probert GK, DeBendetti F, Poli V, Ciliberto G (1998) Interleukin-6 is required for the development of collagen induced arthritis. J Exp Med 187:461–468PubMedCrossRef
24.
go back to reference Ohshima S, Saeki T, Mima T, Sasai M, Nishioka K, Nomura S, Kopf M, Katada Y, Tanaka T, Suemura M, Kishimoto T (1998) Interleukin-6 plays a key role in the development of antigen induced arthritis. Proc Natl Acad Sci USA 95:8222–8226PubMedCrossRef Ohshima S, Saeki T, Mima T, Sasai M, Nishioka K, Nomura S, Kopf M, Katada Y, Tanaka T, Suemura M, Kishimoto T (1998) Interleukin-6 plays a key role in the development of antigen induced arthritis. Proc Natl Acad Sci USA 95:8222–8226PubMedCrossRef
25.
go back to reference Scher JU, Pillinger MH (2005) 15d PGJ2: the anti-inflammatory prostaglandin? Clin Immunol 115:118–128CrossRef Scher JU, Pillinger MH (2005) 15d PGJ2: the anti-inflammatory prostaglandin? Clin Immunol 115:118–128CrossRef
26.
go back to reference Jiang C, Ting AT, Seed B (1998) PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82–86PubMedCrossRef Jiang C, Ting AT, Seed B (1998) PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82–86PubMedCrossRef
27.
go back to reference Fahmi H, Pelletier JP, Martel-Pelletier J (2003) PPAR gamma ligand as modulators of inflammatory and catabolic responses in arthritis: an overview. J Rheumatol 29:3–14 Fahmi H, Pelletier JP, Martel-Pelletier J (2003) PPAR gamma ligand as modulators of inflammatory and catabolic responses in arthritis: an overview. J Rheumatol 29:3–14
28.
go back to reference Beech JT, Andreakos E, Ciesielski CJ, Green P, Foxwell BM, Brennan FM (2006) T cell contact-dependent regulation of CC and CXC chemokine production in monocytes through differential involvement of NFκB: implications for rheumatoid arthritis. Arthritis Res Ther 8:168–177CrossRef Beech JT, Andreakos E, Ciesielski CJ, Green P, Foxwell BM, Brennan FM (2006) T cell contact-dependent regulation of CC and CXC chemokine production in monocytes through differential involvement of NFκB: implications for rheumatoid arthritis. Arthritis Res Ther 8:168–177CrossRef
29.
go back to reference Salmon M, Scheel-Toellner D, Huissoon A, Pilling D, Shamadeen N, Dupuy D’Angeac A, Hyde H, Bacon PA, Emery P, Akbar AN (1997) Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin Invest 99:439–446PubMedCrossRef Salmon M, Scheel-Toellner D, Huissoon A, Pilling D, Shamadeen N, Dupuy D’Angeac A, Hyde H, Bacon PA, Emery P, Akbar AN (1997) Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin Invest 99:439–446PubMedCrossRef
30.
go back to reference Teague TK, Marrack P, Kappler JW, Vella AT (1997) IL-6 rescues resting mouse T cells from apoptosis. J Immunol 158:5791–5796PubMed Teague TK, Marrack P, Kappler JW, Vella AT (1997) IL-6 rescues resting mouse T cells from apoptosis. J Immunol 158:5791–5796PubMed
31.
go back to reference Kobayashi M, Yasui N, Ishimaru N, Arakaki R, Hayashi Y (2004) Development of autoimmune arthritis with aging via bystander T cell activation in the mouse model of Sjogren’s syndrome. Arthritis Rheum 50:3974–3984PubMedCrossRef Kobayashi M, Yasui N, Ishimaru N, Arakaki R, Hayashi Y (2004) Development of autoimmune arthritis with aging via bystander T cell activation in the mouse model of Sjogren’s syndrome. Arthritis Rheum 50:3974–3984PubMedCrossRef
32.
go back to reference Bidinger B, Torres R, Rossetti RG, Brown L, Beltre R, Burstein S, Lian JB, Stein GS, Zurier RB (2003) Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes. Clin Immunol 108:95–102PubMedCrossRef Bidinger B, Torres R, Rossetti RG, Brown L, Beltre R, Burstein S, Lian JB, Stein GS, Zurier RB (2003) Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes. Clin Immunol 108:95–102PubMedCrossRef
33.
34.
go back to reference Johnson DR, Stebulis JA, Rossetti RG, Burstein SH, Zurier RB (2007) Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid. J Cell Biochem 100:184–190PubMedCrossRef Johnson DR, Stebulis JA, Rossetti RG, Burstein SH, Zurier RB (2007) Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid. J Cell Biochem 100:184–190PubMedCrossRef
Metadata
Title
Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid
Authors
Jennifer Parker
Francisco Atez
Ronald G. Rossetti
Ann Skulas
Rakesh Patel
Robert B. Zurier
Publication date
01-05-2008
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 7/2008
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-007-0489-0

Other articles of this Issue 7/2008

Rheumatology International 7/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.